Drug Receives New Indication for Pediatric Graft-Versus-Host... : AJN The American Journal of Nursing

You may be trying to access this site from a secured browser on the server. Please enable scripts and reload this page.

Full Text Access for Subscribers:

You can read the full text of this article if you:

Select an optionLog InBuy ArticleSubscribeContent & PermissionsAccess through Ovid

Log In Access through Ovid

Drug Watch

Aschenbrenner, Diane S. MS, RN

Author Information

Diane S. Aschenbrenner is a former member of the faculty at Notre Dame of Maryland University and the Johns Hopkins University School of Nursing. She coordinates Drug Watch: [email protected].

AJN, American Journal of Nursing:

doi: 10.1097/01.NAJ.0000904084.55613.b6

Metrics Abstract Ibrutinib (Imbruvica) has received a new indication for the treatment of graft-versus-host disease in pediatric patients at least one year of age when one or more systemic therapies have failed. The product's labeling warns of the risk of hemorrhage, infections, cardiac arrythmias, cardiac failure and sudden death, hypertension, cytopenia, secondary primary malignancies, tumor lysis syndrome, and embryo–fetal toxicity. The most common adverse effects include laboratory abnormalities, musculoskeletal pain, pyrexia, pneumonia, abdominal pain, stomatitis, diarrhea, and headache. Nurses should carefully assess for these adverse effects and provide appropriate education regarding their prevention. Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved. Related Articles Article Level Metrics Readers Of this Article Also Read

This website uses cookies. By continuing to use this website you are giving consent to cookies being used. For information on cookies and how you can disable them visit our Privacy and Cookie Policy.